Wenzinger joined the Denver office of Deloitte & Touche in 1972 and became a partner in 1984. She served as the lead client service partner for a variety of private and publicly held clients in health care, insurance, real estate, manufacturing, and oil and gas. Wenzinger possesses extensive Securities and Exchange Commission experience including work on initial public offerings, secondary debt and equity offerings, and compliance reporting.
She served on various national committees for Deloitte & Touche encompassing partner admissions, partner compensation, real estate and health care. Wenzinger retired from Deloitte & Touche in December 2000. She was elected to the Board of Trustees for Delta Dental Plan of Colorado in January 2002 serving as chair of the audit, investment and finance committee as well as a member of the compensation and compliance committees. Her term expired in 2011.
She was appointed to the Board of Directors and chair of the audit committee of Verenium Corp., a NASDAQ-traded biotechnology company in February 2004. Additionally she was appointed to the board of directors and chair of the audit committee for Vicuron Pharmaceuticals, a NASDAQ traded life science company in October 2004. Vicuron was sold to Pfizer in September 2005 and Verenium was sold to BASF in 2013. She was appointed to the Deloitte & Touche Retired Partners Committee in May 2004 and served until 2011. She has served on various nonprofit boards focusing on children, health care and food distribution to the needy and currently serves on the Board of Directors for the University of Northern Colorado Foundation where she chairs the audit and finance committee.